清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Analysis of the tumor microenvironment in ineffective patients of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.

作者
Kazufumi Kobayashi,Sadahisa Ogasawara,Takamasa Ishino,Hidemi Unozawa,Miyuki Nakagawa,Kisako Fujiwara,Takafumi Sakuma,Naoto Fujita,Hiroaki Kanzaki,Keisuke Koroki,Masato Nakamura,Soichiro Kiyono,Naoya Kanogawa,Takayuki Kondo,Tomoko Saito,Ryo Nakagawa,Shingo Nakamoto,Ryosuke Muroyama,Tetsuhiro Chiba,Naoya Kato
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (4_suppl): 468-468
标识
DOI:10.1200/jco.2022.40.4_suppl.468
摘要

468 Background: Atezolizumab plus bevacizumab (Atezo + Bev) has been the standard treatment for frontline systemic therapy in advanced hepatocellular carcinoma (HCC). Immune check point inhibitors and its combination therapies are completely ineffective in some population of patients based on previous reports in several other malignancies. Regarding the results of a phase III trial (IMbrave 150) and several reports from real world practice, ̃20% of patients were determined to be progression disease (PD) as the best radiological response to Atezo + Bev in patients with advanced HCC. In this study, we analyzed the tumor microenvironment using tumor biopsy samples obtained before starting Atezo + Bev to clarify the mechanism of resistance to Atezo + Bev in patients with advanced HCC. Methods: This study enrolled patients with advanced HCC treated with Atezo + Bev at Chiba University Hospital between October 2020 and April 2021. We defined an ineffective group as patients with PD within 2 months according to RECIST version 1.1. The analysis of the tumor microenvironment in this study was performed using the nCounter PanCancer IO 360TM Panel. Results: Of 56 patients who initiated Atezo + Bev during the study period, biopsy samples with a sufficient amount of tumor tissue for analysis were obtained from 30 patients by percutaneous needle biopsy immediately before administering Atezo + Bev. According to radiological assessments, 7 and 23 patients were classified as ineffective and effective groups, respectively. Comparing baseline characteristics of the two groups, the rate of alpha fetoprotein (AFP) ≥ 400 ng/mL was significantly higher in the ineffective group (ineffective group: 85.7%; effective group: 34.8%; p = 0.031). According to gene expression analyses, 101 of 775 genes were differentially expressed between the two groups. Gene set enrichment analysis showed that antigen presentation, cytokine and chemokine signaling, cytotoxicity, immune cell adhesion and migration, and interferon signaling had a lower expression in the ineffective group. Conversely, a higher expression of cell proliferation signaling was observed in the ineffective group. In this cohort, the expression of Wnt signaling showed no significant difference between the two groups. We calculated the cytolytic activity based on the expression of granzyme A and perforin 1, and it was significantly lower in the ineffective group (6.1 in the effective group and 5.3 in the ineffective group, p = 0.013). Conclusions: Analysis of the tumor microenvironment found differences of several gene expressions and those of signaling between the ineffective and effective groups of Atezo + Bev in patients with advanced HCC. The ineffectiveness of Atezo + Bev is due to the reduced action of T cell infiltration and its immune response to tumor.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
耍酷的手套完成签到,获得积分10
1秒前
明亮的小兔子完成签到 ,获得积分10
1秒前
杰西咔发布了新的文献求助10
2秒前
淡然的霆完成签到,获得积分10
3秒前
10秒前
勤奋的猫咪完成签到 ,获得积分10
11秒前
共享精神的应助被杰西咔采纳,获得10
13秒前
13秒前
所所的应助被兰斯洛特117采纳,获得10
14秒前
梵瑾妄完成签到 ,获得积分10
26秒前
35秒前
无花果的应助被兰斯洛特117采纳,获得10
48秒前
虚心问旋完成签到,获得积分10
57秒前
59秒前
高高的仇血完成签到,获得积分10
1分钟前
1分钟前
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
CipherSage的应助被TingtingGZ采纳,获得10
1分钟前
zy997987876完成签到,获得积分10
1分钟前
温婉的连虎完成签到,获得积分10
1分钟前
1分钟前
TingtingGZ发布了新的文献求助10
1分钟前
1分钟前
1分钟前
李红莲完成签到,获得积分10
1分钟前
1分钟前
舒心谷菱完成签到,获得积分10
2分钟前
Raju发布了新的文献求助10
2分钟前
2分钟前
vitamin完成签到 ,获得积分0
2分钟前
2分钟前
喜悦的乐驹完成签到,获得积分10
2分钟前
漂亮秋荷完成签到,获得积分10
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
TingtingGZ完成签到,获得积分10
3分钟前
TingtingGZ发布了新的文献求助10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173161
求助须知:如何正确求助?哪些是违规求助? 9565558
关于积分的说明 21780458
捐赠科研通 7767231
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555697
邀请新用户注册赠送积分活动 2476682